Researchers Develop Smart Nanoparticles to Destroy Proteins That Cause Diseases

Scientists have designed a new class of nanoparticles that can actively remove harmful proteins from the body, a step that could reshape how some of the hardest diseases are treated. Instead of blocking problematic proteins, the approach focuses on eliminating them altogether. 

The research, described in a recent Nature Nanotechnology perspective, is led by Professor Bingyang Shi of the University of Technology Sydney, alongside collaborators at Columbia University and Henan University. 

It builds on earlier experimental work published in 2024 and targets a long-standing limitation in modern medicine; many diseases are driven by proteins that conventional drugs cannot effectively neutralize. In healthy cells, proteins are tightly regulated. When that balance breaks down, through genetic errors, abnormal folding, or excessive accumulation, proteins can begin to interfere with basic cellular processes. 

Professor Shi notes that many of these proteins are difficult to treat because they lack clear binding sites or operate in locations that drugs struggle to reach, particularly in the brain and other protected tissues. 

To overcome this, the team engineered nanoparticles designed to act as precision targeting tools. Known as nanoparticle mediated targeting chimeras, or NPTACs, these particles are built to recognize specific disease related proteins and flag them for removal using the cell’s existing cleanup machinery. The design allows them to function both inside and outside cells and to be adapted for different tissues by modifying their surface components. 

This flexibility sets the platform apart from many current protein degradation technologies. While the field has attracted heavy investment and growing industry attention, existing tools face practical barriers, including limited reach within the body, unintended interactions with healthy proteins, and manufacturing complexity. By relying on well established nanomaterials and modular construction, the NPTAC approach was developed with clinical scalability in mind. 

Early laboratory studies have demonstrated that the nanoparticles can engage proteins linked to major diseases, including EGFR, a driver of tumor growth, and PD-L1, which helps cancer cells evade immune defenses. 

Rather than acting as passive delivery systems, the particles themselves perform the therapeutic function, signaling a shift in how nanoparticles may be used in future treatments. The platform is protected by multiple international patents and is designed to be rapidly reconfigured for new disease targets. 

According to the researchers, this could shorten development timelines and expand the range of conditions that protein degradation strategies can address. As interest in precision medicine continues to grow, the implications extend beyond any single disease area. 

The team is now working to move the technology toward clinical testing and partnerships, with the broader goal of turning smart nanoparticles into adaptable therapeutic tools capable of tackling diseases once considered beyond reach. This work could add a new dimension to other efforts of firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are focused on developing novel treatments for diseases like brain cancer that are currently hard to treat. 

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP 

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN